Clinical Trial Update: A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. [Phase 1]

View source ↗

Summary

This Phase 1 study is evaluating the safety and potential efficacy of WSK-IM02 in patients with platinum-resistant ovarian cancer, with the trial status not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Ovarian Cancer

Drugs mentioned

• WSK-IM02

Snippet

Sponsor: WestVac Biopharma Co., Ltd. | Conditions: Platinum-resistant Recurrent Ovarian Cancer (PROC) | Phase 1 | Status: NOT_YET_RECRUITING